Literature DB >> 8525619

Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor.

Y Lu1, M Wambach, M G Katze, R M Krug.   

Abstract

The NS1 protein of influenza A virus binds not only to poly(A) and a stem-bulge region in U6 small nuclear RNA (snRNA), but also to double-stranded (ds) RNA. Binding assays with NS1 protein mutants established that the previously identified RNA-binding domain of the NS1 protein is required for binding to ds RNA as well as for binding to poly(A) and U6 snRNA. In addition, dsRNA competed with U6 snRNA for binding to the NS1 protein, consistent with both RNAs sharing the same binding site on the protein. As a consequence of its binding to dsRNA, the NS1 protein blocks the activation of the dsRNA-activated protein kinase (PKR) in vitro. This kinase phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (elF-2 alpha), leading to a decrease in the rate of initiation of translation. Assays using purified PKR and purified elF2 demonstrated that the NS1 protein blocks the dsRNA activation of PKR, and experiments using reticulocyte extracts showed that the NS1 protein blocks the inhibition of translation caused by dsRNA activation of PKR. The implications of these results for control mechanisms occurring in influenza virus-infected cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525619     DOI: 10.1006/viro.1995.9937

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  184 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

Review 2.  Cytopathogenesis and inhibition of host gene expression by RNA viruses.

Authors:  D S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein.

Authors:  J Talon; C M Horvath; R Polley; C F Basler; T Muster; P Palese; A García-Sastre
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain.

Authors:  Kevin A Cassady; Martin Gross
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Protein synthesis shut-off induced by influenza virus infection is independent of PKR activity.

Authors:  T Zürcher; R M Marión; J Ortín
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus.

Authors:  T Aragón; S de la Luna; I Novoa; L Carrasco; J Ortín; A Nieto
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice.

Authors:  Nicola R Donelan; Christopher F Basler; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Adeno-associated viruses can induce phosphorylation of eIF2alpha via PKR activation, which can be overcome by helper adenovirus type 5 virus-associated RNA.

Authors:  Ramnath Nayak; David J Pintel
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.